Select Publications

By Associate Professor Charles Edo de Bock

Conference Papers

Bempt MV; de Bock CE; Demeyer S; Vandepoel R; Mentens N; Geerdens E; Radaelli E; Cools J, 2016, 'THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, DENMARK, Copenhagen, pp. 27 - 27, presented at 21st Congress of the European-Hematology-Association, DENMARK, Copenhagen, 09 June 2016 - 12 June 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000379484600057&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Durinck K; Loocke WV; Meulen JVD; Walle IVD; Rondou P; Bock CED; Poppe B; Cools J; Soulier J; Taghon T; Speleman F; Vlierberghe PV, 2015, 'Abstract B05: Transcriptional antagonism between the cooperative oncogenes TLX1 and NOTCH1 in T-cell acute lymphoblastic leukemia.', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. b05 - b05, http://dx.doi.org/10.1158/1557-3265.hemmal14-b05

Durinck K; Vanloocke W; Van der Meulen J; de Walle IV; Rondou P; De Bock C; Verhasselt B; Poppe BG; Cools J; Soulier J; Taghon T; Speleman F; Van Vlierberghe P, 2014, 'Transcriptional Antagonism Between the Cooperative Oncogenes TLX1 and NOTCH1 in T-Cell Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, CA, San Francisco, presented at 56th Annual Meeting of the American-Society-of-Hematology, CA, San Francisco, 06 December 2014 - 09 December 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349233806079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandrine D; de Bock CE; Vicente C; Cox L; Gielen O; Mentens N; Jacobs K; Geerdens E; Tousseyn T; Cools J, 2014, 'JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model', in Blood, American Society of Hematology, pp. 361, http://dx.doi.org/10.1182/blood.v124.21.361.361

de Bock CE; Degryse S; Demeyer S; Sweron B; Gielen O; Mentens N; Geerdens E; Cools J, 2014, 'Synergism Between HOXA9 and Mutant JAK3 (M511I) Leads to Rapid Leukemia Development within an in Vivo Murine Bone Marrow Transplant Model', in Blood, American Society of Hematology, pp. 1078, http://dx.doi.org/10.1182/blood.v124.21.1078.1078

Bempt MV; de Bock CE; Mentens N; Gielen O; Geerdens E; Demeyer S; Cools J, 2014, 'Use of Crispr/Cas Genome Editing in Ba/F3 Cells to Generate the Fip1l1-Pdgfra and Nup214-Abl1 Fusion Genes', in Blood, American Society of Hematology, pp. 3575, http://dx.doi.org/10.1182/blood.v124.21.3575.3575

Peirs S; Matthijssens F; Goossens S; De Bock C; Cante-Barrett K; Lammens T; Van de Walle I; De Moerloose B; Benoit Y; Poppe B; Taghon T; Cools J; Meijerink J; Soulier J; Speleman F; Van Vlierberghe P, 2014, 'ABT-199 MEDIATED INHIBITION OF BCL2 AS A NOVEL THERAPEUTIC STRATEGY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, ITALY, Milan, pp. 539 - 540, presented at 19th Congress of the European-Hematology-Association, ITALY, Milan, 12 June 2014 - 15 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830902361&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Durinck K; Rondou P; de Walle IV; De Bock C; Van Roy N; Benoit Y; Poppe B; Taghon T; Soulier J; Cools J; Van Vlierberghe P; Speleman F, 2014, 'PHF6 LOSS DRIVES IL7R ONCOGENE ADDICTION IN T-ALL', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, ITALY, Milan, pp. 1 - 1, presented at 19th Congress of the European-Hematology-Association, ITALY, Milan, 12 June 2014 - 15 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Bock C; Boyd A; Burn G; Cools J; Thorne R, 2013, 'A UNIQUE FAT1 CADHERIN ISOFORM REGULATES THE PROLIFERATION OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) CELLS', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, pp. 4 - 4, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445772400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Degryse S; Cox L; Gianfelici V; Gielen O; Mentens N; Jacobs K; De Bock C; Cools J, 2013, 'THE ROLE OF JAK3 MUTATIONS IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: DEVELOPMENT OF IN VITRO AND IN VIVO MODELS', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, pp. 467 - 467, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445782800165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sadeqzadeh E; Hersey P; Zhang XD; deBock C; Boyd A; Burns G; Thorne R, 2011, 'Aberrant processing of Fat1 Cadherin in human cancer', in Clinical Biochemistry, Elsevier, pp. s12, http://dx.doi.org/10.1016/j.clinbiochem.2011.08.037

Wang Y; Lin Z; Mekkawy AH; De Bock CE, 2008, 'Interaction between urokinase receptor and heat shock protien enhances cell adhesion', in Challenges to Life Sciences: Molecules and cells, Seoul, Korea, pp. 258 - 258, presented at 9th International Congress on Cell Biology, Seoul, Korea, 07 October 2008 - 10 October 2008

Conference Posters

Van Thillo Q; Lauwereins L; Demeyer S; Provost S; Mentens N; de Bock C; Cools J, 'P347: COOPERATION OF TLX3 AND FLT3‐ITD IN T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA IS ENHANCED BY TLE4 INACTIVATION', Vol. 6, pp. 247 - 248, http://dx.doi.org/10.1097/01.hs9.0000844276.58126.4d

Conference Abstracts

Duchatel R; Jackson E; Parackal S; Sun C; Daniel P; Mannan A; Findlay I; Staudt D; Germon Z; Laternser S; Kiltschewskij D; Kearney P; Jamaluddin MFB; Douglas A; Beitaki T; Perrson M; Thomas B; Manning E; Murray H; Verrills N; Vilain R; Skerrett-byrne D; Nixon B; Hua S; DeBock C; Valdes-Mora F; Tsoli M; Ziegler D; Cairns M; Raabe E; Vitanza N; Phoenix T; Koschmann C; Alvaro F; Dayas C; Tinkle C; Eisenstat D; Firestein R; Mueller S; Nazarian J; Cain J; Dun M, 2023, 'EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 25, pp. v230 - v231, http://dx.doi.org/10.1093/neuonc/noad179.0884

Lock RB; Toscan CE; McCalmont H; Evans K; Doculara L; Kosasih HJ; Gifford AJ; Ashoorzadeh A; Lin X; Trahair TN; De Bock CE; Patterson AV; Smaill JB, 2023, 'The AKR1C3-Activated Prodrug, Achm-025, Eradicates Disease in Preclinical Models of Aggressive T-Cell Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 142, pp. 4251, http://dx.doi.org/10.1182/blood-2023-181298

Murray H; Enjeti AK; Kahl R; Flanagan H; Skerrett-Byrne D; Al-Mazi J; Smith N; de Bock C; Larsen M; Verrills N; Dun M, 2020, 'Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia', in Blood, American Society of Hematology, Vol. 136, pp. 12, http://dx.doi.org/10.1182/blood-2020-142435

Loontiens S; Durinck K; Vanhauwaert S; Depestel L; Oliveira ML; Dewyn G; Bock CD; Barata JT; Langenau D; Cools J; Taghon T; Vlierberghe PV; Speleman F, 2019, 'Abstract 3696: PHF6 loss drives IL7R oncogene addiction in TLX1 driven T-ALL', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 3696 - 3696, http://dx.doi.org/10.1158/1538-7445.am2019-3696

Govaerts I; Gielen O; Habets R; de Bock C; De Keersmaecker K; Segers H; Uyttebroeck A; Maertens J; Boeckx N; De Strooper B; Cools J, 2019, 'PF159 COMBINATION OF SELECTIVE GAMMA‐SECRETASE INHIBITOR MRK‐560 WITH OTHER TARGETED THERAPY IS AN EFFECTIVE AND SAFE TREATMENT FOR T‐ALL', in HemaSphere, Wiley, Vol. 3, pp. 31 - 31, http://dx.doi.org/10.1097/01.hs9.0000558852.50584.54

Verbeke D; de Bock C; Demeyer S; Prieto C; De Bie J; Gielen O; Mentens N; Daelemans D; Uyttebroeck A; Boeckx N; De Keersmaecker K; maertens J; Segers H; Cools J, 2019, 'PF165 THE XPO1 INHIBITOR KPT‐8602 WORKS SYNERGISTIC WITH DEXAMETHASONE TO INHIBIT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS', in HemaSphere, Wiley, Vol. 3, pp. 34 - 35, http://dx.doi.org/10.1097/01.hs9.0000558876.81078.b9

Van Thillo Q; De Bie J; Demeyer S; Tam WL; Sweron B; Geerdens E; Gielen O; Segers H; Boeckx N; Uyttebroeck A; Cools J; de Bock CE, 2019, 'PS916 TCF7‐SPI1 AND NRAS (G12D) COOPERATE IN THE DEVELOPMENT OF T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HemaSphere, Wiley, Vol. 3, pp. 413, http://dx.doi.org/10.1097/01.hs9.0000561944.30888.3a

de Bock C; Habets R; Serneels L; Lodewijckx I; Verbeke D; Nittner D; Narlawar R; Demeyer S; Dooley J; Liston A; Taghon T; de Strooper B; Cools J, 2019, 'PS917 SAFE TARGETING OF T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUBUNIT SELECTIVE GAMMA‐SECRETASE INHIBITION', in HemaSphere, Wiley, Vol. 3, pp. 413 - 414, http://dx.doi.org/10.1097/01.hs9.0000561948.38512.48

Loontiens S; Durinck K; Vanhauwaert S; Depestel L; Oliveira ML; Dewyn G; de Bock C; Barata JT; Langenau D; Cools J; Taghon T; Van Vlierberghe P; Speleman F, 2019, 'PS920 PHF6 LOSS DRIVES IL7R ONCOGENE ADDICTION IN TLX1 DRIVEN T‐ALL', in HemaSphere, Wiley, Vol. 3, pp. 414 - 415, http://dx.doi.org/10.1097/01.hs9.0000561956.76629.c7

Broux M; Prieto C; Demeyer S; Bempt MV; Alberti‐Servera L; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J, 2019, 'S858 SUZ12 INACTIVATION COOPERATES WITH JAK3 MUTANT SIGNALING TO DRIVE T‐ALL DEVELOPMENT', in HemaSphere, Wiley, Vol. 3, pp. 383 - 384, http://dx.doi.org/10.1097/01.hs9.0000561712.29231.fb

Ardjmand A; Bock CED; Molloy TJ; Bone SM; Johnstone D; Campbell DM; Shipman KL; Yeadon TM; Holst J; Spanevello MD; Catchpoole DR; Lincz LF; Boyd AW; Burns GF; Thorne RF, 2011, 'Altered expression of Fat1 cadherin, a novel tumor marker for acute lymphoblastic leukemia', in Clinical Biochemistry, Elsevier, Vol. 44, pp. s71, http://dx.doi.org/10.1016/j.clinbiochem.2011.08.154

Preprints

Germon ZP; Sillar JR; Mannan A; Duchatel RJ; Staudt D; Murray HC; Findlay IJ; Jackson ER; McEwen HP; Douglas AM; McLachlan T; Schjenken JE; Skerrett-Bryne DA; Huang H; Melo-Braga MN; Plank MW; Alvaro F; Chamberlain J; De Iuliis G; Aitken RJ; Nixon B; Wei AH; Enjeti AK; Lock RB; Larsen MR; Lee H; de Bock CE; Verrills NM; Dun MD, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687

Bond DR; Burnard SM; Uddipto K; Hunt KV; Harvey BM; Reinhardt LS; Lawlor-O’Neill C; Roper EA; Humphries S; Murray HC; Mannan A; Dun MD; de Bock CE; Bowden NA; Enjeti AK; Verrills NM; Riveros C; Cao K-AL; Lee HJ, Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal, http://dx.doi.org/10.1101/2024.01.30.577864

Jing D; Beck D; Cao H; Tian F; Huang Y; Zhao H; Tai X; XU W; Kosasih H; Kealy D; Bridge K; Zhao W; Holding A; Dowle A; Taylor S; Song G; Fajardo D; Walia Y; Wang M; Zhang C; Wang J; Mi J-Q; Lock R; de Bock C, PU.1 Eviction at Lymphocyte-Specific Chromatin Domains Mediates Glucocorticoid Response in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.21203/rs.3.rs-3872306/v1

Zhang Q; Li MK; Hu XY; Wang YY; Zhao PP; Cheng LN; Yu RH; Zhang XD; Chen S; Zhu ZM; de Bock CE; Thorne RF, The tumour suppressor Fat1 is dispensable for normal murine hematopoiesis, http://dx.doi.org/10.1101/2023.12.20.572284

Other

Dong L; Jiang CC; Thorne RF; Croft A; Yang F; Liu H; de Bock CE; Hersey P; Zhang XD, 2025, Editorial Expression of Concern: Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress(Oncogene, 10.1038/onc.2011.87), http://dx.doi.org/10.1038/s41388-025-03436-7

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Data from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.c.6529397

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplement from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476449

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 1 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476443

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 1 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476443.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 2 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476440.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 2 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476440

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 3 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476437

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 3 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476437.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476434.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Figure 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476434

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476431

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476431.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 5 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476428.v1

Verbeke D; Demeyer S; Prieto C; de Bock CE; De Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; De Keersmaecker K; Maertens J; Segers H; Cools J, 2023, Supplementary Table 5 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia, http://dx.doi.org/10.1158/1078-0432.22476428

Barz CS; Benford ME; Mishra MK; Chia TS; Cooper E; Newton K; Bonel N; de Bock C; Farenhem K; Zupanc J; Elsanadidy E; Gopinath SD; Winter M; Kemp KC; Nieuwenhuis R; Hoyer JS; Li R; Lindsay G; Li D; O'Mullane A; Schuenemann KC; Ramirez D; Yu SS; Pun M; Li CY, 2016, Measures of success, AMER ASSOC ADVANCEMENT SCIENCE, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373039600017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Bock C, 2016, Measures of success Reply, AMER ASSOC ADVANCEMENT SCIENCE, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373039600052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page

Filter by type

View all »

ORCID as entered in ROS

https://orcid.org/0000-0001-5182-8535